Phase 3 HIV Infections trials: Trial Insights

Filters: Condition: HIV Infections Phase: Phase 3 Clear all

536 trials match Source: ClinicalTrials.gov registrations

Top lead sponsors
Category	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	96
ViiV Healthcare	38
Gilead Sciences	24
French National Agency for Research on AIDS and Viral Hepatitis	21
Bristol-Myers Squibb	20
Merck Sharp & Dohme LLC	19
Glaxo Wellcome	17
Hoffmann-La Roche	17
Boehringer Ingelheim	12
ANRS, Emerging Infectious Diseases	10

Top conditions
Category	Trials
HIV Infections	536
Acquired Immunodeficiency Syndrome	147
AIDS-Related Complex	29
AIDS-Related Opportunistic Infections	22
Sexually Transmitted Diseases	19
Pneumonia, Pneumocystis	18
Infections	16
Tuberculosis	14
Cytomegalovirus Retinitis	9
Hepatitis C	9

Trials

Showing 26 to 50 of 536. Each trial links to its page on Pharma Observatory.

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed NCT04542070Phase 3CompletedViiV HealthcareStarted 2020
Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients NCT04513379Phase 3Unknown statusShanghai Public Health Clinical CenterStarted 2020
A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries NCT04399551Phase 3CompletedViiV HealthcareStarted 2020
Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs NCT04140266Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)Started 2020
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) NCT04223778Phase 3CompletedMerck Sharp & Dohme LLCStarted 2020
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) NCT04223791Phase 3CompletedMerck Sharp & Dohme LLCStarted 2020
Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy NCT03965923Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)Started 2020
AmB Dose for Cryptococcal Meningitis NCT04140461Phase 3Unknown statusShanghai Public Health Clinical CenterStarted 2020
Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA) NCT04021290Phase 3CompletedViiV HealthcareStarted 2019
Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs NCT04034862Phase 3CompletedUniversity of LiegeStarted 2019
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV NCT03284866Phase 3CompletedAIDS Malignancy ConsortiumStarted 2019
Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US) NCT04001803Phase 3CompletedViiV HealthcareStarted 2019
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults NCT03945981Phase 3CompletedViiV HealthcareStarted 2019
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) NCT03512418Phase 3CompletedBrigham and Women's HospitalStarted 2019
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents NCT03682848Phase 3CompletedViiV HealthcareStarted 2019
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE NCT03635788Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)Started 2019
Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan NCT03595709Phase 3CompletedYu-Jay Corp.Started 2018
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen NCT03333083Phase 3TerminatedJudit PichStarted 2018
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM NCT03311945Phase 3CompletedJudit PichStarted 2018
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) NCT03207945Phase 3CompletedUniversity of California, San FranciscoStarted 2018
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants NCT03048422Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)Started 2018
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) NCT03446573Phase 3CompletedViiV HealthcareStarted 2018
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women NCT03164564Phase 3Active, not recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Started 2017
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults NCT03299049Phase 3Active, not recruitingViiV HealthcareStarted 2017
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients NCT03256422Phase 3CompletedANRS, Emerging Infectious DiseasesStarted 2017

436 more trials match. See them on Pharma Observatory

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy NCT05979311Enrollment change307 to 463October 15, 2026
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy NCT05979311Completion date change2027-02-23 to 2027-03-26October 15, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory